About the EntoEngine™ - Our Recombinant Protein Production Platform

The EntoEngine™ harnesses the genetic prowess of Drosophila melanogaster, supercharges it with cutting edge synthetic biology, and scales with the massive efficiencies of insect farming.

With the EntoEngine™, we can optimize production of critical products across a broad range of industries and applications including cellular agriculture, therapeutics, vaccines, growth factors, and enzymes – all within a circular economy framework.

Our goal is to create the largest and most sustainable biomanufacturing platform on the planet

Our insect-based recombinant protein manufacturing platform produces high quality products needed in vaccines, growth media, and therapeutics, but with a 700x to 3000x smaller GHG footprint than existing bioreactor technology.

We have the potential to be a major circular economy player, using waste products to create high quality GMP outputs. We are strong proponents of the triple bottom line, with our ethos being to help people and the planet, while still generating profit. We are aligned with the UN Climate Action Plan, and are proud to be addressing 10 of the 17 UN Sustainable Development Goals.

Zero-waste biomanufacturing is the future, join us to make this future a reality.

We started with growth factors

Future Fields began in the cellular agriculture (cell ag) industry as our platform is uniquely positioned to solve the enormous cost, sustainability, and scale requirements of cell ag.

Our goal is to maximize our platform's positive environmental impact by developing a broad product portfolio which addresses multiple markets. The EntoEngine™ platform addresses multiple challenges across industries, including vaccines, therapeutics, enzymes, cosmetics, and more. We see endless possibilies to create positive change and are excited to work with partners who share this vision for the future.

We started with growth factors for our recombinant protein production

How we do what we do

Here's a brief overview of our process for producing a new recombinant protein of interest with the EntoEngine™:

We first identify the protein to manufacture, then plan, prepare, and clone the sequence into suitable vectors. These vectors are used to insert the sequence that encodes the protein of interest into the Drosophila genome.

After insertion, we expand the population to both increase the quantity of biomass and confirm the presence of the new protein. After we have verified what is called an 'expression stock', we proceed into downstream processing while increasing the volume of biomass into our unit of production, the production block. We continue to extract the proteins of interest for continuous validation and purification and complete the process by conducting a robust panel of safety testing depending on the use case for the protein.

Our Pipeline

2022 Q2
Human prolactin
Bovine TGF beta 1
Bovine PDGF-bb
Human Lactalbumin

 

2022 Q3/Q4
Human Lactoferrin
Porcine NRG1
Porcine Activin A
New Recombinant products

2023
VEGF, IGF-1, TGF beta 3, IL-6, EGF
New Recombinant products

 

We see a future where embracing the full human experience does not compromise the health and viability of humanity and the planet.

WRITING

May 17, 2021

PRESS

A video shoutout by Robert Downey Jr for the Footprint Coalition

May 17, 2021

PRESS

Black and white photo of Future Fields CEO, Matt Anderson-Baron

May 17, 2021